Choudhary Mayur, Ding Jin-Dong, Qi Xiaoping, Boulton Michael E, Yao Pei-Li, Peters Jeffrey M, Malek Goldis
Department of Ophthalmology, Duke University School of Medicine, Durham, NC 27703, USA.
Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Aging (Albany NY). 2016 Sep 8;8(9):1952-1978. doi: 10.18632/aging.101031.
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) is a nuclear receptor that regulates differentiation, inflammation, lipid metabolism, extracellular matrix remodeling, and angiogenesis in multiple tissues. These pathways are also central to the pathogenesis of age-related macular degeneration (AMD), the leading cause of vision loss globally. With the goal of identifying signaling pathways that may be important in the development of AMD, we investigated the impact of PPARβ/δ activation on ocular tissues affected in the disease. PPARβ/δ is expressed and can be activated in AMD vulnerable cells, including retinal pigment epithelial (RPE) and choroidal endothelial cells. Further, PPARβ/δ knockdown modulates AMD-related pathways selectively. Specifically, genetic ablation of in aged mice resulted in exacerbation of several phenotypic features of early dry AMD, but attenuation of experimentally induced choroidal neovascular (CNV) lesions. Antagonizing PPARβ/δ in both angiogenesis assays and in the experimentally induced CNV model, inhibited angiogenesis and angiogenic pathways, while ligand activation of PPARβ/δ, , decreased RPE lipid accumulation, characteristic of dry AMD. This study demonstrates for the first time, selective regulation of a nuclear receptor in the eye and establishes that selective targeting of PPARβ/δ may be a suitable strategy for treatment of different clinical sub-types of AMD.
过氧化物酶体增殖物激活受体-β/δ(PPARβ/δ)是一种核受体,可调节多种组织中的分化、炎症、脂质代谢、细胞外基质重塑和血管生成。这些途径也是全球视力丧失的主要原因——年龄相关性黄斑变性(AMD)发病机制的核心。为了确定在AMD发展中可能重要的信号通路,我们研究了PPARβ/δ激活对该疾病中受影响的眼组织的影响。PPARβ/δ在包括视网膜色素上皮(RPE)和脉络膜内皮细胞在内的易患AMD的细胞中表达并可被激活。此外,PPARβ/δ基因敲低可选择性地调节与AMD相关的途径。具体而言,老年小鼠中PPARβ/δ的基因缺失导致早期干性AMD的几种表型特征加重,但实验诱导的脉络膜新生血管(CNV)病变减轻。在血管生成试验和实验诱导的CNV模型中拮抗PPARβ/δ,可抑制血管生成和血管生成途径,而PPARβ/δ的配体激活可减少干性AMD特征性的RPE脂质积累。这项研究首次证明了眼部核受体的选择性调节,并确定选择性靶向PPARβ/δ可能是治疗不同临床亚型AMD的合适策略。